Zobrazeno 1 - 10
of 10
pro vyhledávání: '"Olivia M. Bates"'
Autor:
George S. Laszlo, Mary E. Beddoe, Colin D. Godwin, Olivia M. Bates, Chelsea J. Gudgeon, Kimberly H. Harrington, Roland B. Walter
Publikováno v:
Haematologica, Vol 104, Iss 2 (2019)
Externí odkaz:
https://doaj.org/article/576b77cf1e4c464f85cfc2b2de7cd1a7
Autor:
Salvatore Fiorenza, Olivier Humbert, Hans-Peter Kiem, Colin D. Godwin, Benjamin G. Hoffstrom, Roland B. Walter, Eliotte E. Garling, Tinh-Doan Phi, George S. Laszlo, Olivia M. Bates, Margaret C. Lunn, Cameron J. Turtle, Colin Correnti
Publikováno v:
Leukemia
There is increasing interest in targeting CD33 in malignant and non-malignant disorders. In acute myeloid leukemia, longer survival with the CD33 antibody-drug conjugate gemtuzumab ozogamicin (GO) validates this strategy. Still, GO benefits only some
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::e98a9e22852fbcca0f249cbcfb813884
https://doi.org/10.1038/s41375-021-01160-1
https://doi.org/10.1038/s41375-021-01160-1
Autor:
George S. Laszlo, Colin D. Godwin, Roland B. Walter, Eliotte E. Garling, Michael H. Cardone, Mary E. Beddoe, Sae Rin Jean, Olivia M. Bates
Publikováno v:
Leuk Lymphoma
Over 26,000 people will face a new diagnosis of acute myeloid leukemia (AML) or acute lymphoblastic leukemia (ALL) in 2020 in the U.S. alone, and only a minority will be long-term survivors [1]. Am...
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::e7b28ca7c38f74944f6eafe4f7f17514
https://doi.org/10.1080/10428194.2020.1786553
https://doi.org/10.1080/10428194.2020.1786553
Autor:
Mary E. Beddoe, Olivier Humbert, Colin D. Godwin, Margaret C. Lunn, Eliotte E. Garling, George S. Laszlo, Zhengwei J. Mao, Roland B. Walter, Hans-Peter Kiem, Brent L. Wood, Colin Correnti, Olivia M. Bates
Publikováno v:
Leukemia
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::b6ff090145586afbac0c51105c28313c
https://doi.org/10.1038/s41375-020-0755-7
https://doi.org/10.1038/s41375-020-0755-7
Autor:
Mary E. Beddoe, Olivia M. Bates, Roland B. Walter, George S. Laszlo, Colin D. Godwin, Eliotte E. Garling
Publikováno v:
Br J Haematol
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::8086a50e4ef602d663745dd03cba3f5a
https://doi.org/10.1111/bjh.16406
https://doi.org/10.1111/bjh.16406
Autor:
Mary E. Beddoe, Ray R. Carillo, Christina Ironside, Kevin G. Haworth, Hans-Peter Kiem, Olivia M. Bates, George S. Laszlo, Olivier Humbert, Sophie R. Sichel, Roland B. Walter
Publikováno v:
Leukemia. 33:762-808
Background:Improved survival with gemtuzumab ozogamicin (GO) in some people with acute myeloid leukemia has validated CD33 as immunotherapeutic target and sparked interested in developing new, highly potent CD33-directed therapeutics. As a limitation
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::a9b5b90f575552ff2cd41b626c95fd70
https://doi.org/10.1038/s41375-018-0277-8
https://doi.org/10.1038/s41375-018-0277-8
Autor:
Colin Correnti, Christopher Mehlin, James M. Olson, Chelsea J. Gudgeon, Colin D. Godwin, Melanie A. Busch, Roland B. Walter, Olivia M. Bates, George S. Laszlo, Willem de van der Schueren, Ashok D. Bandaranayake
Publikováno v:
Leukemia
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::53e774b8ace9e27a501400340ab49ae7
https://doi.org/10.1038/s41375-018-0014-3
https://doi.org/10.1038/s41375-018-0014-3
Autor:
Olivier, Humbert, George S, Laszlo, Sophie, Sichel, Christina, Ironside, Kevin G, Haworth, Olivia M, Bates, Mary E, Beddoe, Ray R, Carrillo, Hans-Peter, Kiem, Roland B, Walter
Publikováno v:
Leukemia. 33(3)
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=pmid________::0a7ef2a94a40c85237432736e1ee8085
https://pubmed.ncbi.nlm.nih.gov/30291334
https://pubmed.ncbi.nlm.nih.gov/30291334
Autor:
Eliotte E. Garling, Michael H. Cardone, Roland B. Walter, Mary E. Beddoe, Sae Rin Jean, Colin D. Godwin, Olivia M. Bates, George S. Laszlo
Publikováno v:
Blood. 134:2561-2561
BACKGROUND: With gemtuzumab ozogamicin (GO; targeting CD33) and inotuzumab ozogamicin (IO; targeting CD22), 2 antibody-drug conjugates delivering a toxic calicheamicin (CLM) derivative have recently been approved for the treatment of people with acut
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::d4c434df5afbe70bd99cb895304fd760
https://doi.org/10.1182/blood-2019-126110
https://doi.org/10.1182/blood-2019-126110
Publikováno v:
Clinical Lymphoma Myeloma and Leukemia. 17:S291
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::a0d4b8bb21d446752d88619943e42983
https://doi.org/10.1016/j.clml.2017.07.079
https://doi.org/10.1016/j.clml.2017.07.079